Table 3 Results of one-way sensitivity analyses of selected parameters
Parameters | Range | Preferred strategy* |
|---|---|---|
Stage I | ||
 Esophagectomy | ||
  Complication** | 0.119–0.35 | EMR |
  Dead | 0.018–0.111 | EMR (ICER of $34,768 for esophagectomy at 0.041) |
  No recurrence to metastasis | 0.002–0.0139 | EMR (ICER of $24,377 for esophagectomy at 0.0109) |
 EMR | ||
  Complication** | 0.030–0.069 | EMR |
  No recurrence to local recurrence | 0.0076–0.0426 | EMR (ICER of $532 for EMR vs EMR followed by ablation at 0.03389) |
 EMR followed by ablation | ||
  Complication** | 0.068–0.222 | EMR |
  No recurrence to local recurrence | 0.014–0.033 | EMR |
  Utility of stage I | 0.66–0.71 | EMR |
  Utility stage II and III | 0.74–0.78 | EMR |
  Utility stage IV | 0.73–0.77 | EMR |
Stage II and III | ||
 Esophagectomy | ||
  Complication** | 0.25–0.39 | CRT followed by surgery |
  Dead | 0.0339–0.111 | CRT followed by surgery |
  No recurrence to dead | 0–0.0905 | At 0.0452, ICER of $3513 for esophagectomy vs CRT followed by surgery |
 CRT followed by surgery | ||
  Complication** | 0.17–0.289 | CRT followed by surgery (at 0.289, ICER of $2373) |
  Dead | 0.04–0.105 | CRT followed by surgery (at 0.105, ICER of $2493) |
 CRT | ||
  Complication** | 0.148–0.28 | CRT followed by surgery |
  Dead | 0.024–0.058 | CRT followed by surgery |
  No recurrence to local recurrence | 0.028–0.0528 | CRT followed by surgery |
  No recurrence to metastasis | 0.0221–0.0139 | CRT followed by surgery |
  Utility stage II and III | 0.74–0.78 | CRT followed by surgery |
  Utility stage IV | 0.73–0.77 | CRT followed by surgery |